KR890011842A - 혈소판활성체인자(paf)의 길항작용을 하는 4-알킬-1,4-디히드로피리딘 화합물 - Google Patents

혈소판활성체인자(paf)의 길항작용을 하는 4-알킬-1,4-디히드로피리딘 화합물 Download PDF

Info

Publication number
KR890011842A
KR890011842A KR1019890000654A KR890000654A KR890011842A KR 890011842 A KR890011842 A KR 890011842A KR 1019890000654 A KR1019890000654 A KR 1019890000654A KR 890000654 A KR890000654 A KR 890000654A KR 890011842 A KR890011842 A KR 890011842A
Authority
KR
South Korea
Prior art keywords
formula
compound
dihydropyridine
ethyl
carboxylate
Prior art date
Application number
KR1019890000654A
Other languages
English (en)
Other versions
KR910008348B1 (ko
Inventor
순께르 까를로스
파우데 까사-하우나 미겔
싼토스 루이스
오르떼가 삘라르
쁘리예고 하이메
싼체스-끄레스뽀 마리아노
Original Assignee
원본미기재
알떼르, 에세.아.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 알떼르, 에세.아. filed Critical 원본미기재
Publication of KR890011842A publication Critical patent/KR890011842A/ko
Application granted granted Critical
Publication of KR910008348B1 publication Critical patent/KR910008348B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

내용 없음

Description

혈소판활성체인자(PAF)의 길항작용을 하는 4-알킬-1,4-디히드로피리딘 화합물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (7)

  1. R은 C₁-C₄가 포함된 직쇄 또는 측쇄알킬기이고, R¹은 C₁-C6가 포함된 직쇄 또는 측쇄알칼기로서, 산 소원자에의해 중단될 수도 있으며, 또한 2-테트라히드로푸르푸릴기로 나타낼 수 있고, R²는 C₁-C₄가 포화된 직쇄알킬기 또는 페닐기로 나타낼 수 있는 식 I에서,
    R은 메틸, R¹은 에틸, R²는 페닐인 화합물은 상기한 식 I에서 제의되는 조건으로 식 I의 PAF 길항작용을 갖는 4-알킬-1,4-디히드로피리딘 화합물.
  2. 제 1항에 있어서,a) 2-(에틸티오)에틸-2,6-디메틸-4-메틸-5-메톡시카르보닐-1,4-디히드로피리딘-3-카르복실레이트와, b) 2-(메틸티오)에틸-2,6-디메틸-4-메틸-5-메톡시카르보닐-1,4-디히드로피리딘-3-카르복실레이트와, c) 2-(메틸티오)에틸-2,6-디메틸-5-에톡시카르보닐-4-메틸-1,4-디히드로피리딘-3-카르복실레이트와, d) 2-(에틸티오)에틸-2,6-디메틸-5-에톡시카르보닐-4-메틸-1,4-디히드로피리딘-3-카르복실레이트와, e) 2-(메틸티오)에틸-2,6-디메틸-4-메틸-5-(2-메톡시에톡시카르보닐)-1,4-디히드로피리딘-3-카르복실레이트와, f) 2-(메틸티오)에틸-2,6-디메틸-4-에틸-5-에톡시카르보닐-1,4-디히드로피리딘-3-카르복실레이트와, g) 2-(메틸티오)에틸-2,6-디메틸-5-에톡시카르보닐-4-n-프로필-1,4-디히드로피리딘-3-카르복실레이트와, h) 2-(에틸티오)에틸-2,6-디메틸-5-에톡시카르보닐-4-n-프로필-1,4-디히드로피리딘-3-카르복실레이트와, i) 2-페닐티오)에틸-2,6-디메틸-4-메틸-5-(2-테트라하이드로푸르푸릴옥시카르보닐)-1,4-디히드로피리딘-3-카르복실레이트와, j) 2-(페닐티오)에틸-2,6-디멜틸-5-이소프로폭시시카르보닐-4-메틸-1,4-디히드로피리딘-3-카르복실레이트와, 2,6-(페닐티오)에틸-2,6-디메틸-4-메틸-5-메톡시카르보닐-1,4-디히드로피리딘-3-카르복실레이트중에서 선택된 PAF 길항작용을 갖는 4-알킬-1,4-디히드로피리딘 화합물.
  3. R은 C₁-C4가 포화된 직쇄 또는 측쇄알킬이고, R¹은 C₁-C6가 포화된 직쇄 또는 측쇄알킬기로서, 산소 원자에의해 중단될 수 있으며, 또한 2-테트라프르푸릴기로 나타낼 수 있고, R2는C₁-C₄가 포화된 직쇄알킬기 또는 페닐기로 나타낼 수 있는 식 I에서,
    a)R과 R¹이 상기한바와같이 정의되는 식 II의 화합물이
    R²가 상기한바와같이 정의되는 식 III의 화합물과,
    반응하여 식 I의 화합물이 생성되고, b) R과 R¹이 상기한 바와같이 정의되는 식 IV의 화합물이
    R¹이 상기한바와같이 정의되는 식 V의 화합물과
    반응하여 식 I의 화합물이 생성되고, c)R¹이 상기한바와같이 정의되는 식 VI의 화합물이
    R²가 상기한바와같이 정의되는 식 III의 화합물과 R이 상기한바와 같이 정의되는 식 VII의 화합물과
    반응하여 식I 의 화합물이 생성되고, d)R²가 상기한바와같이 정의되는 식 VIII의 화합물이
    CH₃-CO-CH₂-COO-(CH₂)₂-S-R² VIII R¹이 상기한바와같이 정의 되는 식 V의 화합물과 R이 상기한바와같이 정의된 식 VII의 화합물과 반응하여 식 I의 화합물이 생성되고, e)R²가 상기한바와같이 정의되는 식 VIII의 화합물이 암모니아 존재하에서 R¹이 상기한바와같이 정의되는 식 VI의 화합물과 R이 상기한바와같이 정의되는 식 VII의 화합물과 반응하여 식 I 의 화합물이 생성되는 것을 특징으로 하는 식 I의 4-알킬-1,4-디히드로피리딘 화합물의 제조방법.
  4. R은 C₁-C₄가 포화된 직쇄 또는 측쇄알킬이고, R¹은 C₁-C₄가 포화된 직쇄 또는 측쇄알킬기로서, 산소 원자에의해 중단될 수도 있으며, 또한 2-테트라푸르푸릴기로 나타낼 수 있고, R²는 C1-C₄가 포화된 직쇄알킬기 또는 페닐기로 나타낼수 있는 식 I의
    4-알킬-1,4-디히드로피리딘의 PAF 길항체로서의 적용.
  5. 제 4 항에 있어서, PAF가 관여하는 병적상태와 질병의 치료를 위한 식 I 화합물의 적용.
  6. 제 4 항과 제 5 항에 있어서, 기관기관지의 염증진행, 급성과 만성기관 지염,천식, 쇼크 또는 알러지의 치료를 위한 식 I 화합물의 적용.
  7. 제 4 항 내지 제 6 항에 있어서,-(페닐티오)에틸-2,6-디메틸-5-에톡시카보닐-4-메틸-1,4-디히드로피리딘-3-카르복실레이트의 응용.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019890000654A 1988-01-21 1989-01-21 혈소판활성체인자(paf)의 길항작용을 하는 4-알킬-1,4-디히드로피리딘 화합물 KR910008348B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DEP3801717.2 1988-01-21
DE3801717A DE3801717C1 (ko) 1988-01-21 1988-01-21
EP91500103A EP0531598A1 (en) 1988-01-21 1991-09-09 1,4-Dihydropyridines with paf-antagonistic activity

Publications (2)

Publication Number Publication Date
KR890011842A true KR890011842A (ko) 1989-08-22
KR910008348B1 KR910008348B1 (ko) 1991-10-12

Family

ID=40279084

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890000654A KR910008348B1 (ko) 1988-01-21 1989-01-21 혈소판활성체인자(paf)의 길항작용을 하는 4-알킬-1,4-디히드로피리딘 화합물

Country Status (19)

Country Link
EP (2) EP0325187B1 (ko)
JP (2) JPH01233273A (ko)
KR (1) KR910008348B1 (ko)
AR (1) AR248137A1 (ko)
BR (1) BR9203580A (ko)
CA (2) CA1332838C (ko)
CZ (1) CZ278692A3 (ko)
DE (1) DE3801717C1 (ko)
DK (1) DK25989A (ko)
ES (1) ES2052783T3 (ko)
FI (1) FI924018A (ko)
GR (1) GR3006934T3 (ko)
HU (1) HUT65253A (ko)
IE (2) IE890136L (ko)
MX (1) MX9204642A (ko)
NO (1) NO923489L (ko)
PL (1) PL295861A1 (ko)
PT (2) PT89494B (ko)
ZA (2) ZA89519B (ko)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3801717C1 (ko) * 1988-01-21 1989-05-24 Alter S.A., Madrid, Es
WO1996004268A1 (fr) * 1994-07-29 1996-02-15 Nikken Chemicals Co., Ltd. Compose de 1,4-dihydropyridine et composition medicinale contenant ledit compose
EP1052990A2 (en) 1997-11-14 2000-11-22 Neurosearch A/S Chemical compounds having ion channel blocking activity for the treatment of immune dysfunction
US6566359B1 (en) 2002-05-20 2003-05-20 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College 2,4,6-trimethyl-1,4-dihydro-pyridine-3,5-dicarboxylic acid esters as neuroprotective drugs
WO2016144995A1 (en) * 2015-03-09 2016-09-15 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions and methods for the treatment of glioblastoma

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2747513A1 (de) * 1977-10-22 1979-05-03 Bayer Ag Dihydropyridine mit schwefelhaltigen estergruppierungen
US4761420A (en) * 1986-06-13 1988-08-02 Laboratoires Syntex S.A. Antihypertensive dihydropyridine derivatives
DE3801717C1 (ko) * 1988-01-21 1989-05-24 Alter S.A., Madrid, Es

Also Published As

Publication number Publication date
HUT65253A (en) 1994-05-02
JPH05208958A (ja) 1993-08-20
IE922412A1 (en) 1993-03-10
MX9204642A (es) 1993-12-01
KR910008348B1 (ko) 1991-10-12
EP0325187B1 (en) 1992-11-11
AR248137A1 (es) 1995-06-30
DK25989A (da) 1989-07-22
GR3006934T3 (ko) 1993-06-30
BR9203580A (pt) 1993-04-13
CA1332838C (en) 1994-11-01
JPH0552827B2 (ko) 1993-08-06
ZA89519B (en) 1989-10-25
ES2052783T3 (es) 1994-07-16
PT89494B (pt) 1994-03-31
HU9202873D0 (en) 1992-11-30
NO923489D0 (no) 1992-09-08
CA2074419A1 (en) 1993-03-10
FI924018A (fi) 1993-03-10
FI924018A0 (fi) 1992-09-08
ZA925692B (en) 1993-03-02
JPH0742271B2 (ja) 1995-05-10
DK25989D0 (da) 1989-01-20
PT89494A (pt) 1989-10-04
JPH01233273A (ja) 1989-09-19
EP0531598A1 (en) 1993-03-17
EP0325187A1 (en) 1989-07-26
CZ278692A3 (en) 1993-12-15
PT100848A (pt) 1993-10-29
PL295861A1 (en) 1993-05-04
NO923489L (no) 1993-03-10
IE890136L (en) 1989-07-21
DE3801717C1 (ko) 1989-05-24

Similar Documents

Publication Publication Date Title
KR830009054A (ko) 아미노피리미딘 유도체의 제조방법
KR830001926A (ko) 신규한 퀴나조린 유도체 및 그의 부가염의 제조방법
KR950005827A (ko) 신규 2- 아미노티아졸카르복사미드 유도체, 그의 제조방법 및 식물병원균 퇴치를 위한 그의 용도
KR840004741A (ko) 디히드로피리딘 유도체의 제조방법
RU2002132897A (ru) Соединения пиперазиндиона
SE8303910L (sv) 15-deoxi-hydroxiprostaglandiner och forfarande for framstellning derav
EP0092158A3 (en) Thiazolidine compound and fungicidal composition containing it
KR860007209A (ko) 트리치환 안식향산 중간체의 제법
KR930002311A (ko) N-페닐티오우레아 유도체 및 그의 약학적 용도
KR850003719A (ko) 시아노피라졸 제초제에 대한 개량
KR890011842A (ko) 혈소판활성체인자(paf)의 길항작용을 하는 4-알킬-1,4-디히드로피리딘 화합물
KR900016190A (ko) 2-페닐피리딘
NO179368C (no) Arylimidazoler med pesticidvirkning, anvendelse derav, og preparater inneholdende slike
KR840005715A (ko) 3-페녹시-1-아제티딘 카아복사마이드의 제조방법
KR880700798A (ko) 신규한 인데노티아졸유도체 및 그 제조법
KR900016178A (ko) 2-치환 n,n'-디트리메톡시벤조일 피페라진, 그의 제조 방법 및 그를 함유하는 치료 조성물
KR840008342A (ko) 모르포린 유도체의 제조방법
KR910004544A (ko) 신규 아조페닐 화합물, 이를 함유한 조성물, 이의 제조 방법 및 살균제로서 이들의 이용
KR830009085A (ko) (피리딘일)-y-벤즈이미다졸
KR880005110A (ko) 이미노옥사졸리딘 및 그 제조방법
KR860001789A (ko) 디히드로피리딘 유도체의 제조방법
DK0485204T3 (da) Fremgangsmåde til fremstilling af 3-alkoxymethyl-cephalosporin-derivater
KR960014107A (ko) 피리미디닐 아크릴산 유도체
KR910016703A (ko) 플루오로메틸-치환 피페리딘 카보디티오에이트의 제조방법
DE69119714T2 (de) Verfahren zur Herstellung von Benzylphthalazinonderivaten und von deren Salzen

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 19950810

Year of fee payment: 5

LAPS Lapse due to unpaid annual fee